Profile data is unavailable for this security.
About the company
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
- Revenue in CAD (TTM)0.00
- Net income in CAD-2.66m
- Incorporated2011
- Employees3.00
- LocationXORTX Therapeutics Inc3710 - 33rd Street NWCALGARY T2L 2M1CanadaCAN
- Phone+1 (403) 455-7727
- Fax+1 (403) 607-2621
- Websitehttps://www.xortx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appili Therapeutics Inc | 212.30k | -2.53m | 2.57m | 7.00 | -- | -- | -- | 12.09 | -0.0209 | -0.0209 | 0.0018 | -0.1287 | 0.1839 | -- | 0.786 | -- | -219.60 | -143.75 | -- | -1,382.22 | -- | -- | -1,194.04 | -2,076.82 | -- | -2.80 | -- | -- | -87.86 | -12.79 | 30.58 | -- | 16.92 | -- |
| Rakovina Therapeutics Inc | 0.00 | -8.36m | 3.60m | -- | -- | 1.90 | -- | -- | -0.5705 | -0.5705 | 0.00 | 0.0893 | 0.00 | -- | -- | -- | -158.14 | -- | -221.29 | -- | -- | -- | -- | -- | -- | -21.46 | 0.579 | -- | -- | -- | -55.86 | -- | -- | -- |
| XORTX Therapeutics Inc | 0.00 | -2.66m | 4.39m | 3.00 | -- | 1.21 | -- | -- | -0.6481 | -0.6481 | 0.00 | 0.5192 | 0.00 | -- | -- | -- | -58.35 | -39.11 | -94.63 | -43.59 | -- | -- | -- | -- | -- | -- | 0.0291 | -- | -- | -- | -53.53 | -- | 48.96 | -- |
| Telo Genomics Corp | 0.00 | -2.71m | 4.52m | 8.00 | -- | -- | -- | -- | -0.0289 | -0.0289 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -517.19 | -98.53 | -51,970.82 | -111.33 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2116 | -- | -- | -- |
| StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.87m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1235 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0177 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Quest PharmaTech Inc | 0.00 | -96.59k | 5.07m | 0.00 | -- | 0.2198 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.1365 | 0.00 | -- | -- | -- | -0.398 | 10.66 | -0.4181 | 11.12 | -- | -- | -- | -- | -- | -- | 0.0415 | 0.00 | -- | -- | 40.32 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Citadel Securities LLCas of 30 Sep 2025 | 86.33k | 1.24% |
| XTX Markets LLCas of 30 Sep 2025 | 13.82k | 0.20% |
| UBS Securities LLCas of 31 Dec 2025 | 1.40k | 0.02% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 358.00 | 0.01% |
| Clearstead Advisors, LLCas of 30 Sep 2025 | 277.00 | 0.00% |
| SBI Securities Co., Ltd.as of 30 Sep 2025 | 1.00 | 0.00% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Sep 2025 | 0.00 | 0.00% |
